3.8

CiteScore

2.4

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Chen Li, Jie Yu, Tian Wu, Qingxia Lin, Rui Hua, Zihang Zhong, Yule Li, Kun Liu, Li Zhu, Naiquan Yang, Xin Chen, Xiaoyan Wang, Xin Zhao, Jun Jiang, Bo Zhao, Xiwen Zhang, Pengsheng Chen, Tong Wang, Yi Xu, Gaoyong Liao, Liang Yuan, Bo Chen, Zhihui Xu, Xiaoxuan Gong, Wenhao Zhang, Chunyue Tan, Lei Xu, Qiang Huang, Jianling Bai, John W Eikelboom, Chunjian Li. 1-year outcomes of single bolus r-SAK before primary PCI for STEMI: The follow-up of OPTIMA-5[J]. Journal of Biomedical Research. DOI: 10.7555/JBR.39.20250043
Citation: Chen Li, Jie Yu, Tian Wu, Qingxia Lin, Rui Hua, Zihang Zhong, Yule Li, Kun Liu, Li Zhu, Naiquan Yang, Xin Chen, Xiaoyan Wang, Xin Zhao, Jun Jiang, Bo Zhao, Xiwen Zhang, Pengsheng Chen, Tong Wang, Yi Xu, Gaoyong Liao, Liang Yuan, Bo Chen, Zhihui Xu, Xiaoxuan Gong, Wenhao Zhang, Chunyue Tan, Lei Xu, Qiang Huang, Jianling Bai, John W Eikelboom, Chunjian Li. 1-year outcomes of single bolus r-SAK before primary PCI for STEMI: The follow-up of OPTIMA-5[J]. Journal of Biomedical Research. DOI: 10.7555/JBR.39.20250043

1-year outcomes of single bolus r-SAK before primary PCI for STEMI: The follow-up of OPTIMA-5

  • The Optimal Management of Antithrombotic and Thrombolytic Agents-5 (OPTIMA-5) study demonstrated that a single bolus of half-dose recombinant staphylokinase (r-SAK) before primary percutaneous coronary intervention (PCI) significantly improved the patency of the infarct-related artery in patients with ST-segment elevation myocardial infarction (STEMI) expected to undergo PCI within 120 min. This study aimed to investigate the 1-year clinical outcome and the effect of the r-SAK antibody on a second r-SAK thrombolysis in OPTIMA-5 patients. The clinical outcome was major adverse cardiovascular events (MACE) within 360 days. Patients' r-SAK antibody levels were determined on day 90 (± 7 days), day 180 (± 7 days), and 360 (± 14 days) after thrombolysis, and in vitro r-SAK antibody neutralization experiments were performed to explore an optimal interval for a second r-SAK thrombolysis. Results showed that the MACE incidence was numerically lower in the r-SAK group compared with the normal saline (NS) group (14.0% vs. 20.0%, hazard ratio HR = 0.67, 95% confidence interval CI: 0.34–1.32; log-rank P = 0.245). The r-SAK antibody levels in the r-SAK group decreased with time, but remained significantly higher than those in the NS group on day 90 (± 7 days) (2.96 ± 0.68 vs. 0.22 ± 0.53, P < 0.001), day 180 (± 7 days) (2.19 ± 0.74 vs. 0.44 ± 0.65, P < 0.001), and day 360 (± 14 days) (1.73 ± 0.97 vs. 0.37 ± 0.71, P < 0.001). The in vitro r-SAK antibody neutralization experiments illustrated that the thrombolysis rate decreased exponentially as the antibody titer increased from 1.90 to 2.20 (67.80% ± 14.19% vs. 44.32% ± 21.54%, P < 0.0001). Therefore, for STEMI patients expected to undergo PCI within 120 min, a single bolus of half-dose r-SAK before primary PCI may reduce the 1-year MACE risk. The r-SAK antibody lasts over one year, and a second r-SAK thrombolysis may not be indicated until one year after the first r-SAK thrombolysis if necessary.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return